The estimated Net Worth of Marviette D. Johnson is at least $1.62 Milion dollars as of 2 March 2015. Marviette Johnson owns over 1,917 units of Meridian Bioscience stock worth over $1,585,380 and over the last 13 years Marviette sold VIVO stock worth over $38,167.
Marviette has made over 1 trades of the Meridian Bioscience stock since 2015, according to the Form 4 filled with the SEC. Most recently Marviette sold 1,917 units of VIVO stock worth $38,167 on 2 March 2015.
The largest trade Marviette's ever made was selling 1,917 units of Meridian Bioscience stock on 2 March 2015 worth over $38,167. On average, Marviette trades about 274 units every 0 days since 2011. As of 2 March 2015 Marviette still owns at least 46,670 units of Meridian Bioscience stock.
You can see the complete history of Marviette Johnson stock trades at the bottom of the page.
Marviette's mailing address filed with the SEC is 3471 RIVER HILLS DRIVE, , CINCINNATI, OH, 45244.
Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny oraz John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian Bioscience executives and other stock owners filed with the SEC include: